ArticleCureus2025
Impact of a Standardized Gastrografin Protocol on Small Bowel Obstruction Outcomes at a Community Hospital: A Retrospective and Prospective Cohort Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small bowel obstruction (SBO) is a common condition in general surgical practice. This study aimed to determine whether the use of an oral hyperosmolar contrast agent (Gastrografin) combined with serial abdominal radiographs improves patient outcomes compared with standard management of SBO in a community hospital. A retrospective and prospective analysis was conducted of patients admitted with SBO over a two-year period. The retrospective control group included patients from January 2022 through December 2022, while the prospective group included those from January 2023 through December 2023. Exclusion criteria were emergent operative intervention, recent abdominal surgery (<30 days), and age <18 years. Patients treated with a standardized Gastrografin protocol were compared with those managed conventionally. Primary outcomes included length of stay (LOS), number of CT scans, progression to surgery, and 30-day readmission rates. Ninety patients met the inclusion criteria; 24 received the Gastrografin protocol, and 66 received standard care. The Gastrografin group had a significantly shorter LOS (2.2 ± 1.4 vs. 4.6 ± 4.2 days, p < 0.001) and underwent fewer CT scans (1.0 ± 0.0 vs. 1.4 ± 0.6, p < 0.001). Rates of surgical intervention (4.2% vs. 21.2%, p = 0.06) and 30-day readmission (12.5% vs. 15.2%, p = 1.00) did not differ significantly between groups. The findings suggest that a standardized Gastrografin protocol may reduce hospital LOS and CT utilization in the management of SBO at community hospitals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.